An economic result belongs to a healthcare setting and a set of assumptions. It is not a timeless property of a hormone preparation. Primary report
Model snapshot
This economic evaluation used two randomized IVF trials involving 986 women and a simulation model to compare highly purified hMG with recombinant FSH-alpha in the United Kingdom. Under its inputs, hMG was both less costly and more effective. The analysis considered cost per cycle and cost per live birth; it was published in 2009 after online publication in 2008. Primary report
Our appraisal: identify what was observed and what was modeled
Trial outcomes and economic projections are different evidence layers. A model combines observed information with assumptions about resource use, unit costs, and treatment pathways. Its output should not be described as though every projected expenditure was a directly observed bill.
“Dominant” has a specific economic meaning: less costly and more effective within the comparison. It is not a claim of clinical superiority across all circumstances. A different price structure or patient mix could change the modeled conclusion without invalidating the original calculation.
Present-day affordability also depends on whose perspective is used. A public payer, clinic, insurer, and patient may face different costs. An older UK estimate should not become a current Canadian or US treatment quote through simple currency conversion.
This report reuses trial evidence rather than supplying an independent efficacy replication. Its distinct contribution is the resource-allocation question. A modern application would need refreshed prices, explicit currency and price year, sensitivity analyses, and a clearly stated treatment pathway. This page explains the historical model; it does not recommend an individual fertility purchase or claim current savings.
Frequently asked questions
Was this solely a new clinical trial?
No; it was an economic evaluation using trial data and modeling.
Which setting framed the cost conclusion?
The United Kingdom.
What does economic dominance mean?
Lower cost and greater effectiveness within the modeled comparison.
Are its prices current quotes?
No.
Does currency conversion update the whole model?
No; care pathways and resource prices also matter.
Is it independent confirmation of the source trials' efficacy?
No.
What would a current analysis require?
Updated inputs, a defined perspective, and uncertainty analysis.